Apotex filed an emergency motion in the U.S. Court of Appeals for the District of Columbia Circuit on Monday, seeking a stay of the U.S. Food and Drug Administration's award of exclusivity to Teva, as well as a stay on approval of all abbreviated new drug applications related to the drugs.